BIOLINERX LTD-SPONS ADR (BLRX)
US09071M2052 - ADR
BIOLINERX LTD-SPONS ADR
NASDAQ:BLRX (12/20/2024, 8:00:01 PM)
After market: 0.2084 +0.01 (+2.66%)0.203
+0 (+0.5%)
Company Profile
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Company Info
BIOLINERX LTD-SPONS ADR
Modi'in Technology Park, 2 HaMa'ayan Street
Modiin 7177871
P: 97286429100
CEO: Philip A. Serlin
Employees: 79
Website: https://www.biolinerx.com/
BLRX News
a month ago - BioLineRx Ltd.BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as...
a month ago - BioLineRx Ltd.BioLineRx to Report Third Quarter 2024 Results on November 25, 2024/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
3 months ago - BioLineRx Ltd.BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
4 months ago - InvestorPlaceBLRX Stock Earnings: BioLine Rx Beats Revenue for Q2 2024BLRX stock results show that BioLine Rx beat on revenue for the second quarter of 2024.
4 months ago - BusinessInsiderBLRX Stock Earnings: BioLine Rx Beats Revenue for Q2 2024InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ:BLRX) just reported results for the second quarter of 2024.T...
4 months ago - BioLineRx Ltd.BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal...
BLRX Twits
Here you can normally see the latest stock twits on BLRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
